Drug/Device Combos With Cross-Labeling To Generics May Pose Liability Risks
Executive Summary
Drug/device cross-labeling to generics poses added liability problems, stakeholders at a recent Regulatory Affairs Professional Society meeting said
You may also be interested in...
Industry Hopes FDA’s New Combo Products Chief Speeds Up Pending Rules
FDA's Office of Combination Products says it is getting back on track with new leadership in place after months of flux. Industry meanwhile is pushing the office to accelerate the release of rules and guidelines to help companies navigate this relatively new area of regulation
Industry Hopes FDA’s New Combo Products Chief Speeds Up Pending Rules
FDA's Office of Combination Products says it is getting back on track with new leadership in place after months of flux. Industry meanwhile is pushing the office to accelerate the release of rules and guidelines to help companies navigate this relatively new area of regulation
Drug/Device Combo Safety Monitoring Is Cooperation Barrier, Pfizer Says
Concerns about how to conduct postmarket safety surveillance are major impediments to the development of cross-labeled combination products, Pfizer Medical & Development Sciences Executive Director David Eveleth said